Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience

Luciana Melo Garcia, Tzu-Fei Wang, Michael Kennah, Abdullah Alanazi, Sarah Mckeague, John Kuruvilla, Inna Gong, Naomi Marali Xiao, Christopher Lemieux, Camille Sylvestre, Amaris Balitsky, Isabelle Fleury, Mathias Castonguay, Robert Puckrin, Hannah Cherniawsky, Amani Ahmed, Mahmoud Elsawy, Maggie McGuire, Miriam Kimpton

Blood (2025) 146 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2025-4496

Published: 2025

Journal Articles

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes

Sergio Rodriguez-Rodriguez, Nihar Desai, Brittany Salter, Amani Ahmed, Mohamed Elemary, Jonas Mattsson, Kylie Lepic, Jennifer White, Dennis Kim

Blood (2025) 146 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2025-2470

Published: 2025

Journal Articles

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Sergio Rodriguez-Rodriguez, Rebeca Bailen, Keven Vachon, Brittany Salter, Christopher Lemieux, Kareem Jamani, Mohamed Elemary, Sylvie Lachance, Jonas Mattsson, Kylie Lepic, Amani Ahmed, Jennifer White, Felipe Peña-Muñoz, Juan Alberto Martín González, Jose Antonio Perez Simon, Matthias Fante, Daniel Wolff, Mi Kwon, Dennis Kim

Blood (2025) 146 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2025-4239

Published: 2025

Journal Articles

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure

Blood (2025) 146 (Supplement 1): 6031.

https://doi.org/10.1182/blood-2025-6031

Published: 2025

Journal Articles

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.

Blood (2025) 146 (Supplement 1): 6025.

https://doi.org/10.1182/blood-2025-6025

Published: 2025

Journal Articles

Excellent Outcome of Myeloablative TBI-Based Allogeneic Stem Cell Transplant in Adult Patients with Acute Lymphocytic Leukemia in MRD Negative CR1: Results from a Retrospective Canadian Cohort

Amani Ahmed, Hannah Cherniawsky, Shanee Chung, Donna L. Forrest, Deepesh Lad, Florian Kuchenbauer, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Judith Anula Rodrigo, Claudie Roy, David Sanford, Kevin Song, Ryan J Stubbins, Cynthia L. Toze, Jennifer White, Yasser Abou Mourad

Blood (2024) 144 (Supplement 1): 7417.

https://doi.org/10.1182/blood-2024-206077

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.

Excellent Outcome of Myeloablative TBI-Based Allogeneic Stem Cell Transplant in Adult Patients with Acute Lymphocytic Leukemia in MRD Negative CR1: Results from a Retrospective Canadian Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure

Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.

Excellent Outcome of Myeloablative TBI-Based Allogeneic Stem Cell Transplant in Adult Patients with Acute Lymphocytic Leukemia in MRD Negative CR1: Results from a Retrospective Canadian Cohort

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only